Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Assets: 2019-2025

Historic Assets for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Mar 2025 value amounting to $21.7 million.

  • China SXT Pharmaceuticals' Assets fell 14.98% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year decrease of 14.98%. This contributed to the annual value of $21.7 million for FY2025, which is 6.33% down from last year.
  • China SXT Pharmaceuticals' Assets amounted to $21.7 million in FY2025, which was down 6.33% from $23.1 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Assets ranged from a high of $34.5 million in FY2021 and a low of $21.7 million during FY2025.
  • Its 3-year average for Assets is $24.8 million, with a median of $23.1 million in 2024.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Assets surged by 59.19% in 2021 and then dropped by 21.75% in 2024.
  • China SXT Pharmaceuticals' Assets (Yearly) stood at $34.5 million in 2021, then decreased by 2.90% to $33.5 million in 2022, then fell by 11.90% to $29.6 million in 2023, then declined by 21.75% to $23.1 million in 2024, then dropped by 6.33% to $21.7 million in 2025.